Kailera Therapeutics, Inc.
Key Metrics
- Previous Close
- $17.17
- 52-Week Range
- $16.37 – $28.23
- Market Cap
- $2.14B
- P/E (TTM)
- —
- EPS (TTM)
- -2.25
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 1.92
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- —
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 11.11
- Debt/Equity
- 0.01
- Total Debt
- $10.22M
- Free Cash Flow
- —
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.24B
Market Snapshot
About
Kailera Therapeutics, Inc. (KLRA) is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing novel drug therapies for the treatment of obesity and related metabolic diseases.
The company maintains a pipeline of drug candidates in both clinical and preclinical stages of development. Its programs are designed to target various pathways using different administration methods, including injectable peptides, oral peptides, and oral small molecules. Specific assets include a dual agonist and a tri-agonist of key metabolic receptors, as well as an oral small molecule agonist. Kailera aims to create effective treatment options that may offer patients and physicians flexibility in how therapies are delivered.
Kailera Therapeutics holds exclusive global rights for the development and commercialization of four key metabolic disease assets, with certain regional restrictions. Its business strategy involves advancing these therapeutic candidates through clinical trials to demonstrate their safety and efficacy, with the goal of ultimately seeking regulatory approval and commercialization. The company was founded in 2024.